# Treatment of Non-small Cell Lung Cancer With PD-1 Monoclonal Antibody Combined With Donafenib Toluene Sulfonate

> **NCT04059874** · PHASE1 · UNKNOWN · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 20 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** donafenib tablets

## Key facts

- **NCT ID:** NCT04059874
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-31
- **Primary completion:** 2020-07-31
- **Final completion:** 2020-11-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04059874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04059874, "Treatment of Non-small Cell Lung Cancer With PD-1 Monoclonal Antibody Combined With Donafenib Toluene Sulfonate". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04059874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*